Molecular mechanism(s) of resistance to vandetanib in medullary thyroid carcinoma.

被引：0
|
作者：
Glassberg, Brittany
Khan, Sophia
Pemov, Alex
Hawley, Robert
Widemann, Brigitte C.
Khan, Javed
Glod, John
机构：
[1] NIH, Bldg 10, Bethesda, MD 20892 USA
[2] NCI, Pediat Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[3] NCI, NIH, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15628
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [1] MOLECULAR MECHANISM(S) OF RESISTANCE TO VANDETANIB IN MEDULLARY THYROID CARCINOMA
    Glassberg, Brittany
    Khan, Sophia
    Pemov, Alex
    Hawley, Bob
    Widemann, Brigitte
    Khan, Javed
    Glod, John
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S116 - S116
  • [2] Vandetanib for the Treatment of Medullary Thyroid Carcinoma
    Cooper, Maryann R.
    Yi, Soo Yun
    Alghamdi, Wael
    Shaheen, Daniel J.
    Steinberg, Michael
    ANNALS OF PHARMACOTHERAPY, 2014, 48 (03) : 387 - 394
  • [3] Reversal of Cushing's Syndrome by Vandetanib in Medullary Thyroid Carcinoma
    Baudry, Camille
    Paepegaey, Anne-Cecile
    Groussin, Lionel
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (06): : 584 - 586
  • [4] YAP confers resistance to vandetanib in medullary thyroid cancer
    Wang, Huan
    Tang, Jian
    Su, Zhiwei
    BIOCHEMISTRY AND CELL BIOLOGY, 2020, 98 (03) : 443 - 448
  • [5] Hypercalcitoninemia out of medullary thyroid carcinoma.
    Niccoli, P
    ConteDevolx, B
    Lejeune, PJ
    Carayon, P
    Henry, JF
    Roux, F
    WionBarbot, N
    Bigorgne, JC
    ANNALES D ENDOCRINOLOGIE, 1996, 57 (01) : 15 - 21
  • [6] Vandetanib In Medullary Thyroid Cancer
    Frampton, James E.
    DRUGS, 2012, 72 (10) : 1423 - 1436
  • [7] Use of Neoadjuvant Vandetanib in Aggressive Pediatric Medullary Thyroid Carcinoma
    Kothari, Ronik
    Kreimer, Sara
    Nadel, Helen
    Seeley, Hilary
    Hartman, Gary
    Meister, Kara D.
    JCO PRECISION ONCOLOGY, 2024, 8
  • [8] Pathology of hypercalcitoninemia without medullary thyroid carcinoma.
    StAndre, JP
    Guyetant, S
    ANNALES D ENDOCRINOLOGIE, 1996, 57 (01) : 23 - 26
  • [9] Progress in Molecular Targeted Therapy for Thyroid Cancer: Vandetanib in Medullary Thyroid Cancer
    Solomon, Benjamin
    Rischin, Danny
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (02) : 119 - 121
  • [10] Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma
    Durante, Cosimo
    Paciaroni, Alessandra
    Plasmati, Katia
    Trulli, Fabiana
    Filetti, Sebastiano
    ENDOCRINE, 2013, 44 (02) : 334 - 342
12345